FDA approves Lilly’s Zepbound for obstructive sleep apnea
Lilly’s stock was up slightly in after-hours trading.
Eli Lilly & Co.
-
IBJ Podcast: What’s the potential impact of Lilly’s $4.5B ‘medicine foundry’ in Lebanon?
Lilly wants to know how to improve new medicines and speed them to market more quickly. The project promises hundreds of high-paying jobs and could help lift Lilly among a handful of the most valuable companies in America.
Read More -
Lilly’s new weight-loss drug is a ‘double wow’ and likely blockbuster
The pharmaceutical giant is turning heads with an experimental medicine it claims can help obese patients shed nearly a quarter of their body weight and manage diabetes.
Read More -
Lilly acquiring gene therapy startup for up to $1 billion
Eli Lilly and Co. on Tuesday announced that it is buying New York-based Prevail Therapeutics Inc., an emerging player in the sizzling-hot area of gene therapies, which targets Parkinson’s disease and other brain-related maladies.
Read More -
Business leaders say focus must remain on racial inequality for years to come
During IBJ’s Engage Indiana 2020 virtual event Thursday morning, Eli Lilly & Co. CEO Dave Ricks said he always believed enhancing diversity and inclusion was important, but this year showed him how serious a problem racial injustice is and fueled his motivation to do more to address it.
Read More
Articles
Lilly shares get bump from pricey Biden proposal for covering weight-loss drugs
While the proposed rule would give millions of people access to weekly injectables like Eli Lilly and Co.’s Zepbound that have helped people shed pounds, it would cost taxpayers as much as $35 billion over the next decade.
Lilly’s $3.7B manufacturing campus in Boone County starting to take shape
The company plans to develop at least 12 buildings totaling more than 1.6 million square feet. The project is expected to anchor the LEAP Research and Innovation District northwest of Lebanon.
Biden sees $35 price cap for insulin as pivotal campaign issue
Rarely a day goes without President Joe Biden mentioning insulin prices and promoting a $35 price cap for the medication for Americans on Medicare. The reality is more complicated.
Lilly signs another AI deal, this one for obesity
Fauna Bio, based in the San Francisco area, said Thursday it will give Lilly access to its AI platform, called Convergence, to support preclinical drug discovery efforts in obesity.
Indy Chamber exec joins developer working on Boone County innovation district
Ian Nicolini, who has served as Indy Chamber’s chief operating officer since October 2020, is leaving his position to join a commercial real estate developer working to recruit businesses to a high-tech research district planned in Boone County.
Editorial: Impact of abortion ban demands review
Indiana ended up with a rushed law that seemed to please few.
Elements CEO stepping down after 17 years leading credit union
Lisa Schlehuber has served as CEO of Indianapolis-based Elements Financial since 2005. She’ll retire from the role in April, the credit union announced Wednesday.
While rivals Pfizer and Moderna scoop up millions in vaccine profits, Lilly is about to show its hand
Eli Lilly and Co. passed up the chance to develop a vaccine and instead focused on making antibody treatments for patients who were already infected with the coronavirus. That turned out to be a financial whiff. Now all eyes will be on Lilly’s second-quarter earnings, which the company will release early Tuesday.
Lilly buys California diabetes biotech in deal potentially worth $1 billion
The Indianapolis-based drugmaker said the deal to buy Protomer Technologies could be worth up to $1 billion if the technology meets certain milestones. Lilly did not say how much it was paying up front in cash.
UPDATED: Lilly antibody drug fails in COVID-19 study for hospitalized patients
The discontinuation of the study, along with the release of third-quarter earnings that fell short of analysts’ expectations, caused Lilly shares to fall 3.5% in premarket trading Tuesday.
Eli Lilly, hospitals go to war over drug prices
A long-simmering dispute between Eli Lilly and Co. and safety-net hospitals across the nation over the price of prescription drugs has reached the boiling point.
Pharma giant Lilly to help Indiana health officials with COVID-19 testing
State officials have taken sharp criticism in the last week for the slow pace of testing. Through Tuesday, the Indiana State Department of Health had conducted 193 tests, out of which 39 were presumed positive.
Eli Lilly asking employees to work from home due to coronavirus
Indianapolis-based Lilly, the 12th largest employer in Indiana with 10,600 workers in the state, said it didn’t have a specific timeline for how long the precaution would last.
Lilly adding two more insulin options to discount program
Under fire over insulin prices, the Indianapolis-based drugmaker said Tuesday morning it is introducing lower-priced versions of its Humalog KwikPen and Humalog Junior KwikPen.
5 things to look for Thursday in Lilly’s earnings
Executives at Eli Lilly and Co. are telling investors the worst is behind the company and only good things await. But the drugmaker still has a few things to prove.
Lilly CEO: Drugmakers getting bum rap
Eli Lilly and Co. CEO John Lechleiter told Wall Street analysts recently that, while there have been “individual huge drug price increases,” the overall cost of drugs is rising very slowly and remains a small part of overall U.S. health care spending.
Eskenazi launches $50M effort to take brain care around the world
The safety-net hospital system in Indianapolis will create the Center for Brain Care Innovation and try to use telemedicine and a digital avatar to reach as many as 150,000 Hoosiers and 10 million patients outside Indiana by 2030.
Go figure: As patients’ anger over costs spikes, health care prices barely budge
Patients’ anger over high deductibles and high drug prices is spurring presidential candidates to respond—even as the actual prices of health care services are growing slower than at any time since 1990.
Analyst: Lilly’s Jardiance diabetes pill could be a $6 billion-a-year blockbuster
It looks like Eli Lilly and Co. finally has a drug that can replace its former stars Zyprexa and Cymbalta. The most bullish analysts think Jardiance can surpass those $5 billion-a-year blockbusters.